Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.

Taofeek K Owonikoko,Huifeng Niu,Kristiaan Nackaerts,Tibor Csoszi,Gyula Ostoros, Zsuzsanna Mark,Christina Baik,Anil Abraham Joy,Christos Chouaid,Jesus Corral Jaime,Vitezslav Kolek,Margarita Majem,Jaromir Roubec,Edgardo S Santos,Anne C Chiang,Giovanna Speranza,Chandra P Belani,Alberto Chiappori,Manish R Patel, Krisztina Czebe,Lauren Byers,Brittany Bahamon,Cong Li,Emily Sheldon-Waniga,Eric F Kong, Miguel Williams, Sunita Badola,Hyunjin Shin, Lisa Bedford,Jeffrey A Ecsedy, Matthew Bryant, Sian Jones,John Simmons,E Jane Leonard,Claudio Dansky Ullmann,David R Spigel

Journal of Thoracic Oncology（2020）

引用 93|浏览88

暂无评分

摘要

Efficacy signals were seen with alisertib/paclitaxel in relapsed/refractory SCLC. c-Myc expression and mutations in cell cycle regulators may be potential predictive biomarkers of alisertib efficacy; further prospective validations are warranted.

查看译文

关键词

Phase II,Aurora A kinase,Alisertib,Paclitaxel,SCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要